Skip to Main Content

Paper Details

Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.
Genet Med
10
2022
Author NameAffiliation
Paolo RadiceFondazione IRCCS Istituto Nazionale dei Tumori (INT)
Alberto Zambelli
Georgia Chenevix-TrenchQIMR Berghofer Medical Research Institute
Georgia Chenevix-TrenchQIMR Berghofer Medical Research Institute
Esther M JohnDepartment of Epidemiology & Population Health and Stanford Cancer Institute, Stanford University
Mary Beth TerryMailman School of Public Health, Columbia University, NY Herbert Irving Comprehensive Cancer Center
Irene L AndrulisFred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, University of Toronto
Irene L AndrulisFred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, University of Toronto
Judy E GarberCenter for Cancer Genetics and Prevention, Dana-Farber Cancer Institute
Christi J van AsperenLeiden University Medical Center
Susan M DomchekBasser Center for BRCA, Abramson Cancer Center, University of Pennsylvania
Heather ThorneThe University of Melbourne
Sarah M NielsenCenter for Clinical Cancer Genetics, The University of Chicago
Siranoush ManoukianFondazione IRCCS Istituto Nazionale dei Tumori
Judy KirkCrown Princess Mary Cancer Centre, Westmead Hospital, Sydney Medical School, University of Sydney, The Westmead Institute for Medical Research
Amanda B SpurdleQIMR Berghofer Medical Research Institute
Amanda B SpurdleQIMR Berghofer Medical Research Institute
Fergus J CouchMayo Clinic
Fergus J CouchMayo Clinic
David E GoldgarHuntsman Cancer Institute, University of Utah, University of Utah School of Medicine
David E GoldgarHuntsman Cancer Institute, University of Utah, University of Utah School of Medicine
  • 1 - 21

Datasets